Aug 01, 2018 9:54am EDT UPDATE: Nemus Bioscience, Inc. Signs Agreement with Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredient for Glaucoma
Aug 01, 2018 8:30am EDT Nemus Bioscience, Inc. Signs Agreement with Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredient for Glaucoma
Mar 21, 2018 8:30am EDT Prominent Salk Institute Neuroscientist Joins Nemus Bioscience as Scientific Consultant
Mar 07, 2018 8:30am EST NEMUS Bioscience to Participate in Sachs BioCapital USA Forum at the New York Academy of Sciences
Feb 16, 2018 5:24pm EST Emerald Health, Strategic Majority Investor in Nemus Bioscience, Completes Final Closing of Private Placement Investment Ahead of Schedule
Feb 07, 2018 8:30am EST NEMUS Bioscience to Participate in BIO CEO Investor Conference to Provide Ophthalmology-Focused Pipeline Review
Jan 19, 2018 8:30am EST Nemus Secures Emerald Health as Strategic Majority Investor to help Advance Clinical Development of Novel Cannabinoid-based Therapeutics
Dec 29, 2017 8:30am EST Nemus Bioscience Announces Closing of Convertible Bridge Loan and Anticipated Equity Financing